Is Pomegranate Blood Flow Randomized Trial safe?

Updated June 2026

Quick Answer

Pomegranate Blood Flow Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort.

Key Takeaways

  • 01Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026)]
  • 02Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026)]
  • 03Previous clinical studies have examined effects of polyphenol-rich interventions on fasting trimethylamine N-oxide (TMAO) concentrations but have not assessed pharmacokinetic TMAO responses following an oral carnitine challenge (OCC). [Haarhuis JE (2026)]
  • 04PSO significantly reduced histological injury: Median total injury score was 9 (7-11) in IR, 6 (4-8) in IR + PSO low, and 3 (2-5) in IR + PSO high ( P < 0.001). [Altimimi MLM (2026)]
The current Migaku evidence database contains 2 reusable source documents for Pomegranate Blood Flow Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026); evidence level 2] - Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026); evidence level 2] - Previous clinical studies have examined effects of polyphenol-rich interventions on fasting trimethylamine N-oxide (TMAO) concentrations but have not assessed pharmacokinetic TMAO responses following an oral carnitine challenge (OCC). [Haarhuis JE (2026); evidence level 2] - PSO significantly reduced histological injury: Median total injury score was 9 (7-11) in IR, 6 (4-8) in IR + PSO low, and 3 (2-5) in IR + PSO high ( P < 0.001). [Altimimi MLM (2026); evidence level 4] - Multivariable logistic regression showed that PSO treatment was associated with lower odds of severe IR injury (odds ratio: 0.40, 95% confidence interval: 0.18-0.90). [Altimimi MLM (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Effect of a polyphenol-rich pomegranate extract on plasma trimethylamine N-oxide levels following an oral carnitine challenge: a randomized controlled crossover trial in healthy adults.
  2. Effects of pomegranate seed oil on lower-extremity ischemia-reperfusion damage: Insights into oxidative stress, inflammation, and cell death.